Compare ARK Genomic Revolution ETF (ARKG) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Marvell Technology Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.21, while Marvell Technology Inc trades at $230.8 (market cap $206.99B). The key difference: Marvell Technology Inc pays a 0.1% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Marvell Technology Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | MRVL | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $316.43 |
52-Week Low | $23.09 | $62.31 |
Market Cap | — | $206.99B |
Enterprise Value | — | $208.42B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Marvell Technology (MRVL) trades at $235.81, down 3.07% on the day, with a neutral technical signal despite bullish moving averages. The company shows strong profitability margins but elevated valuation ratios, with a P/E of 81.03. Recent quarters have consistently beaten EPS estimates, and analyst consensus is overwhelmingly bullish with an 82.19% buy rating and a $275 price target. Cash flow trends indicate improving operational performance, though net income has been negative historically, with a projected turnaround to $2.5B net profit in 2026.
The outlook for MRVL is positive, driven by AI infrastructure growth engines and a strategic partnership with Nvidia, positioning it for significant revenue expansion. Risks include high valuation multiples, competitive pressures in the semiconductor space, and reliance on continued AI investment. The stock presents a growth opportunity if execution matches guidance, but investors should be cautious of volatility and earnings sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
